Watch Damian Wild discuss the role of nuclear medicine physicians in multidisciplinary oncology tumor boards, strategies for engaging oncologists in the theranostics-related management of their patients, and the future of dosimetry in clinical practice. He also shares valuable insights for young professionals exploring opportunities in theranostics.

Maribel del Olmo reviewed the advantages and disadvantages of somatostatin analogs for patients with somatostatin receptor-positive neuroendocrine tumors, the evolving treatment landscape for these patients, the necessary steps if a non-functional NET becomes functional during radiopharmaceutical therapy, and the promising advancements in innovative radiopharmaceuticals.

This webcast is from the satellite symposium titled “HOW TO SPEAK ‘THERANOSTICS’ IN NET: Translating Key Principles into Clinical Practice” that took place at the European Neuroendocrine Tumor Society (ENETS) Annual Congress on 6^th March 2025 in Krakow, Poland.